Wenbo Wu

Mr. Wenbo Wu

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2026 in Cancer Letters
Verified
Journal Article
Open access
YDYijun Dong
Yijun Dong
TLTingyu Liang
Tingyu Liang
JLJunlin Li
Junlin Li
LWLingxiang Wu
Lingxiang Wu
LGLingui Gu
Lingui Gu
YWYu Wang
Yu Wang
Glioblastoma (GBM) exhibits marked spatial and cellular heterogeneity, driving aggressive progression and therapy resistance. Utilizing multifocal GBM as a unique model of tumor evolution, we integrated multi-omics including scRNA-seq, scATAC-seq, and spatial transcriptomics (ST). This revealed a subcluster of bone marrow-derived macrophages (BMDMs), NUPR1+ myeloid-derived suppressor cells (MDSCs), enriched in peri-necrotic niches and higher-evolution lesions. Supported by multiplex immunofluorescence (mIF) and ultrastructural analyses, these MDSCs spatially co-localized and actively engaged in functional crosstalk with mesenchymal-like (MES) tumor cells. NUPR1+ MDSCs upregulated hypoxia and ferroptosis-resistance pathways and expressed a core Spatial-MDSC-Ferroptosis (SMF) program that independently predicted poor survival, irrespective of hypoxia, and correlated with a reduced response to neoadjuvant anti-PD-1 therapy. Epigenetic profiling revealed CEBPA as a core transcriptional regulator orchestrating the SMF program. In vitro, ferroptosis induction in macrophages promoted migration and mesenchymal transition of co-cultured GBM cells, phenotypes that were effectively reversed by ferrostatin-1 (Fer-1) and pazopanib. These findings reveal a spatially defined, ferroptosis-resistant myeloid niche driving MES tumor progression, providing mechanistic insights into myeloid-tumor interactions and identifying the myeloid compartment as a potential therapeutic target in GBM.

20 March 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
CHChunhua Hu
Chunhua Hu
XYXin Yang
Xin Yang
XKXiaoman Kang
Xiaoman Kang
TLTingyu Liang
Tingyu Liang
WWWenbo Wu
Wenbo Wu
YWYu Wang
Yu Wang
BackgroundTumor treating fields (TTFields) improve survival in glioblastoma (GBM), but their clinical efficacy is limited by inefficient electric-field delivery through the high-impedance scalp and skull. This attenuation reduces intratumoral electric field, increases superficial heating, and contributes to treatment-related dermatologic toxicity.MethodsWe propose an intracranial-implanted coupled-electrode TTFields strategy (ICE-TTF), in which a single depth electrode implanted in the tumor cavity is coupled with distributed extracranial counter-electrodes. Finite-element modeling was used to optimize electrode geometry and evaluate electric-field and thermal distributions. A segmented intracranial electrode was examined for directional field switching. Therapeutic efficacy was assessed in rat glioma models using bioluminescence imaging and histology. Impedance monitoring and electrochemical assays were performed to evaluate interface behavior and electrode safety.ResultsICE-TTF generated therapeutically relevant tumor electric fields with substantially lower power and minimal temperature rise compared with external TTFields. Segmented contacts enabled switching between predominantly radial and tangential field components. In vivo, ICE-TTF suppressed tumor growth and reduced proliferative activity. Electrode–tissue impedance correlated with tumor progression, supporting its potential as a monitoring biomarker. Electrochemical modeling, ion-release measurements, and histology confirmed the stability and biocompatibility of PtIr electrodes under high-frequency stimulation.ConclusionsICE-TTF introduces an intracranial–extracranial coupled electrode architecture that improves TTFields energy delivery efficiency using a single implanted electrode while enabling directional field modulation and impedance-based monitoring. This strategy may provide a minimally invasive and energy-efficient platform for adaptive electric-field therapy in glioblastoma.

17 June 2026 in Brain Stimulation
Verified
Journal Article
Open access
XYXin Yang
Xin Yang
XKXiaoman Kang
Xiaoman Kang
TLTingyu Liang
Tingyu Liang
WWWenbo Wu
Wenbo Wu
HXHao Xing
Hao Xing
CHChunhua Hu
Chunhua Hu
Tumor treating fields (TTFields) improve survival in glioblastoma (GBM), but their clinical efficacy is limited by inefficient electric-field delivery through the high-impedance scalp and skull. This attenuation reduces intratumoral electric-field intensity and increases superficial power deposition, while external arrays remain associated with skin-interface complications. We propose an intracranial-implanted coupled-electrode TTFields strategy (ICE-TTF), in which a single depth electrode implanted in the tumor cavity is coupled with distributed extracranial counter-electrodes. Finite-element modeling was used to optimize electrode geometry and evaluate electric-field and thermal distributions. A segmented intracranial electrode was examined for directional field switching. Short-term anti-tumor activity was assessed in rat glioma models using bioluminescence imaging and histology. Impedance monitoring and electrochemical assays were performed to evaluate interface behavior, short-term electrode stability, and tissue response. In simulations, ICE-TTF generated tumor electric-field intensities within the TTFields-relevant range with substantially lower power and lower temperature rise than external TTFields under matched coverage assumptions. Segmented contacts enabled switching between predominantly radial and tangential field components. In vivo, ICE-TTF attenuated the BLI-derived tumor-burden signal and reduced proliferative activity. Electrode-tissue impedance was associated with BLI-derived tumor-burden progression, supporting its potential as a candidate monitoring signal. Electrochemical modeling, ion-release measurements, and short-term histology supported short-term electrochemical stability and peri-electrode tissue compatibility of Pt-Ir electrodes under the tested high-frequency stimulation conditions. ICE-TTF represents a candidate reduced-implant-burden intracranial TTFields delivery architecture. The current data support simulation-based field-delivery feasibility, short-term proof-of-concept anti-tumor activity, and future impedance-informed monitoring, while direct comparative efficacy, survival benefit, and closed-loop control remain to be validated.

9 November 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
XZXin Zhang
Xin Zhang
WWWenbo Wu
Wenbo Wu
YWYu Wang
Yu Wang
XLXin Lian
Xin Lian
WMWenbin Ma
Wenbin Ma
This review explores the nuanced decision-making surrounding postoperative radiotherapy for diffuse low-grade glioma patients, emphasizing the need for individualized treatment to balance the benefits of tumor control with the risks of side effects. Radiotherapy is a cornerstone of diffuse low-grade glioma treatment, offering significant improvements in progression-free survival, but its potential for quality of life necessitates careful consideration of individual patient factors. The review delves into the radiotherapy timing, revealing that while early radiotherapy enhances progression-free survival, it does not significantly impact overall survival and may lead to severe and prolonged decline in long-term quality of life. Conversely, delayed radiotherapy may mitigate these side effects. The review advocates for a patient-centered approach, emphasizing the importance of weighing individual risks and benefits, and highlights the potential of artificial intelligence in predicting quality of life and the need to revisit previous research findings in light of the 2021 WHO (World Health Organization) classification update, underscoring the evolving nature of low-grade glioma treatment and the ongoing quest for optimal therapeutic strategies.

30 April 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
YGYulu Ge
Yulu Ge
ZHZhan Hu
Zhan Hu
WWWenbo Wu
Wenbo Wu
WMWenbin Ma
Wenbin Ma
TLTingyu Liang
Tingyu Liang
YWYu Wang
Yu Wang
Background: Chromosome 7 gain (chr7 gain) is a highly prevalent early event in glioblastoma (GBM). Because chr7 gain usually involves broad chromosomal amplification, its biological impact is unlikely to be fully explained by canonical loci such as EGFR and MET. The contribution of less-characterized, dosage-sensitive genes on chromosome 7 remains insufficiently defined. This study aimed to identify additional chr7 candidates associated with malignant phenotypes in GBM. Methods: Transcriptomic, copy-number, and clinical data from TCGA-GBM and TCGA-LGG were analyzed to characterize chr7-gain-associated alterations and prioritize candidate genes. Refined GBM and histologic GBM cohorts based on the WHO 2021 framework were used for candidate selection. RPA3-associated pathway features were examined using ssGSEA, PROGENy, WGCNA, and protein–protein interaction analysis, with external validation in the CGGA-693 cohort. Single-cell RNA-seq analysis compared chr7-gain and chr7-normal-copy tumor subclusters. Functional relevance was evaluated by siRNA-mediated knockdown in U87 and U118 cells. Results: Chr7 gain was enriched in high-grade IDH-wildtype gliomas and was associated with cell-cycle- and DNA repair-related programs. RPA3 was prioritized as a dosage-sensitive chromosome 7 candidate based on its upregulation in chr7-gain tumors, association with poor prognosis, and concordance with replication- and repair-related signatures. In vitro, RPA3 knockdown impaired cell growth, proliferation, colony formation, and migration. Single-cell analysis suggested greater transcriptomic and network-level relevance of RPA3 in chr7-gain tumor cells. Conclusions: RPA3 is a dosage-sensitive chromosome 7 candidate associated with aggressive and replication-/repair-related phenotypes in GBM. Increased RPA3 expression may contribute to the selective advantage associated with chr7 gain, which supports further investigation as potential therapeutic target.